Loading…
Loading…
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company's audit committee and board of directors approved a change in the Company's auditors from DNTW Toronto LLP (the "Former Auditor") to Horizon Assurance LLP (the "Successor Auditor"), effective June 6, 2025. There were no reservations in the Former Auditor's reports for the two most recently completed fiscal years or for any period after the most recently completed period for which an audit report was issued and preceding the date of the Former Auditor's resignation.
Toronto, Ontario--(Newsfile Corp. - December 6, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") provides an update on its previously announced private placement. Further to the news release dated October 21, 2024, the Company intends to complete a non-brokered private placement offering (the "Offering") of up to 33,333,333 units ("Units"), at a price of $0.015 per Unit, for total gross proceeds of up to approximately $500,000.
Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has received an order from the British Columbia Securities Commission (the "BCSC") revoking the management cease trade order (the "MCTO") previously granted by the BCSC on August 29, 2024. As previously announced, the MCTO was granted by the BCSC at the Company's request on August 29, 2024, due to delays in filing the Company's annual audited consolidated financial statements for the financial year ended April 30, 2024, the related annual management's discussion and analysis and the related CEO and CFO certifications (collectively, the "Annual Filings").
Toronto, Ontario--(Newsfile Corp. - October 24, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by its principal regulator, the British Columbia Securities Commission (the "BCSC"), under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). The Company announced on August 14, 2024 (the "Default Announcement"), that it expected to be unable to file its annual audited consolidated financial statements for the financial year ended April 30, 2024, the related annual management's discussion and analysis and the related CEO and CFO certifications (collectively, the "Annual Filings") by the filing deadline of August 28, 2024 (the "Filing Deadline") and last provided an update on the status of the MCTO on October 10, 2024.
Toronto, Ontario--(Newsfile Corp. - October 23, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company"), through its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), is excited to announce the appointment of Charles Freihofer as its new Chief Revenue Officer ("CRO"). Mr. Freihofer joined Toppen in mid-September to lead the organization's renewed focus on revenue and earnings.
Toronto, Ontario--(Newsfile Corp. - October 21, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement offering (the "Offering") of up to 33,333,333 units ("Units"), at a price of $0.015 per Unit, for total gross proceeds of up to approximately $500,000. Each Unit will consist of one common share ("Share") and one half of one common share purchase warrant ("Warrant").
Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by its principal regulator, the British Columbia Securities Commission (the "BCSC"), under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). The Company announced on August 14, 2024 (the "Default Announcement"), that it expected to be unable to file its annual audited consolidated financial statements for the financial year ended April 30, 2024, the related annual management's discussion and analysis and the related CEO and CFO certifications (collectively, the "Annual Filings") by the filing deadline of August 28, 2024 (the "Filing Deadline") and last provided an update on the status of the MCTO on September 26, 2024.
Toronto, Ontario--(Newsfile Corp. - September 26, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by its principal regulator, the British Columbia Securities Commission (the "BCSC"), under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). The Company announced on August 14, 2024 (the "Default Announcement"), that it expected to be unable to file its annual audited consolidated financial statements for the financial year ended April 30, 2024, the related annual management's discussion and analysis and the related CEO and CFO certifications (collectively, the "2024 Financial Disclosure") by the filing deadline of August 28, 2024 (the "Filing Deadline") and last provided an update on the status of the MCTO on September 12, 2024.
No recent filings indexed.